Amicus Therapeutics Acquisition: BioMarin Deal Shifts Rare Disease Portfolio and Valuation Focus

BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for an expected Q2 2026 close. The deal will fold Amicus' marketed rare disease drugs and late-stage pipeline into BioMarin's commercial portfolio. As an investor, patient, or employee, the center of gravity for Amicus' assets is expected to shift to BioMarin once the deal closes.